吉列德科学和美CDC就HIV事先预防(PrEP)药的专利归属首次互撕在公堂!美CDC于2019就起诉吉列德科学没支付PrEP的2个口服药专利费,GILD对此说法坚决予以否认;CDC科学家在新的千禧第一个10年发现,2种抗艾药emtricitabine和tenofovir组合在一起,可高效预防HIV感染;吉列德科学的Truvada和Descovy均含emtricitabine/tenofovir,202...
The article offers information that AIDS Healthcare Foundation (AHF) commented on the new guidance from the U.S. Centers for Disease Control and Prevention (CDC) for the expansion of the use of AIDS treatment drug Truvada from Gilead Sciences Inc. as pre-exposure prophylaxis (PrEP) from gay ...
研究发现,每天服用固定剂量的替诺福韦和恩曲他滨(即Truvada)可以长期有效地预防HIV感染。美国CDC建议下列哪些高危人群接受暴露前预防(PrEP)的措施()A.男男
PrEP 是一种新的为HIV阴性的人群设计的药。每天一颗,一周到两周后开始奏效。每天吃这个药可以使HIV阴性的人跟阳性的人有性接触也不会感染,99%的保护率。美国FDA已经批准两年多了并且鼓励HIV高危人群持续服用。中国似乎还知名度不是很高。现在应该还在医药公司的专利期内所以价格不低,但是专利期过后有望降低。相关...
RESULTS. 31,347 unique patients had PrEP-related testing. Of those, 25,373 had one or more tests with 146 (0.6%) testing positive for HIV at baseline. 14,480 unique patients had two or more HIV PrEP tests on different dates. 98% were male with a median age of 36 years. 20 of ...
该诉讼声称吉利德“夸大”了其在开发舒发泰的HIV预防方案(PrEP,即暴露前预防)中的作用,忽视了CDC的贡献,并拒绝许可CDC的专利。 2023年,吉利德通过在美国销售舒发泰和达可辉获得了超过18亿美元的收入。政府在庭前文件中表示,其有权因舒发泰和达可辉分别获得高达6.91亿美元和3.11亿美元的的损害赔偿。
"While a vaccine or cure may one day end the HIV epidemic, PrEP is a powerful tool that has the potential to alter the course of the U.S. HIV epidemic today," Dr. Jonathan Mermin, director of CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, said in the...
HIV testing venues The potential impact of PrEP implementation at CDC-funded nonclinical HIV testing venuesThe potential impact of PrEP implementation at CDC-funded nonclinical HIV testing venuesVanessa M Kung
『科普』♀12-19..You can get or transmit HIV only through specific activities. Most commonly, people get or transmit
近日,美国食品药品监督管理局(FDA)批准ViiV Healthcare研发的长效注射针剂卡博特韦(cabotegravir,英文商品名Apretude),用于体重≥35公斤(77磅)的高风险成人和青少年进行HIV暴露前预防(PrEP)。这是全球首款无需每日服药的长效PrEP方案。 PrEP的重大突破 HIV...